JP2011507858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507858A5 JP2011507858A5 JP2010539514A JP2010539514A JP2011507858A5 JP 2011507858 A5 JP2011507858 A5 JP 2011507858A5 JP 2010539514 A JP2010539514 A JP 2010539514A JP 2010539514 A JP2010539514 A JP 2010539514A JP 2011507858 A5 JP2011507858 A5 JP 2011507858A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- connexin
- polynucleotide
- drug
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 99
- 108091033319 polynucleotide Proteins 0.000 claims description 83
- 239000002157 polynucleotide Substances 0.000 claims description 83
- 102000040430 polynucleotide Human genes 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 72
- 230000000692 anti-sense effect Effects 0.000 claims description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims description 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- 241000124008 Mammalia Species 0.000 claims description 30
- 241001465754 Metazoa Species 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 102000001045 Connexin 43 Human genes 0.000 claims description 23
- 108010069241 Connexin 43 Proteins 0.000 claims description 23
- 230000000399 orthopedic effect Effects 0.000 claims description 22
- 239000000816 peptidomimetic Substances 0.000 claims description 22
- 238000001356 surgical procedure Methods 0.000 claims description 18
- 108020004999 messenger RNA Proteins 0.000 claims description 16
- 239000002773 nucleotide Substances 0.000 claims description 16
- 125000003729 nucleotide group Chemical group 0.000 claims description 16
- 102000010970 Connexin Human genes 0.000 claims description 12
- 108050001175 Connexin Proteins 0.000 claims description 12
- 208000002193 Pain Diseases 0.000 claims description 10
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 8
- 108091030071 RNAI Proteins 0.000 claims description 8
- 108020004459 Small interfering RNA Proteins 0.000 claims description 8
- 230000000295 complement effect Effects 0.000 claims description 8
- 230000009368 gene silencing by RNA Effects 0.000 claims description 8
- 238000002844 melting Methods 0.000 claims description 8
- 230000008018 melting Effects 0.000 claims description 8
- 230000004962 physiological condition Effects 0.000 claims description 8
- 238000011084 recovery Methods 0.000 claims description 8
- 208000027418 Wounds and injury Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 208000014674 injury Diseases 0.000 claims description 6
- 244000144972 livestock Species 0.000 claims description 6
- 230000004899 motility Effects 0.000 claims description 6
- 101800005309 Carboxy-terminal peptide Proteins 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 230000006916 protein interaction Effects 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 206010023201 Joint contracture Diseases 0.000 claims description 2
- 208000004550 Postoperative Pain Diseases 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 210000003976 gap junction Anatomy 0.000 claims description 2
- 239000005022 packaging material Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- 230000002980 postoperative effect Effects 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- 230000003966 vascular damage Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 31
- 229940079593 drug Drugs 0.000 claims 29
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 230000003828 downregulation Effects 0.000 claims 1
- 125000002796 nucleotidyl group Chemical group 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US883407P | 2007-12-21 | 2007-12-21 | |
| PCT/US2008/014022 WO2009085271A2 (en) | 2007-12-21 | 2008-12-22 | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507858A JP2011507858A (ja) | 2011-03-10 |
| JP2011507858A5 true JP2011507858A5 (enExample) | 2013-04-25 |
Family
ID=40824956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539514A Pending JP2011507858A (ja) | 2007-12-21 | 2008-12-22 | 整形外科状態の治療のための、単独のまたは抗コネキシンポリヌクレオチドと組み合わせた、抗コネキシンペプチドの使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20110243964A1 (enExample) |
| EP (1) | EP2242844A2 (enExample) |
| JP (1) | JP2011507858A (enExample) |
| AU (1) | AU2008343842A1 (enExample) |
| CA (1) | CA2710382A1 (enExample) |
| WO (1) | WO2009085271A2 (enExample) |
| ZA (1) | ZA201005218B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2596412A1 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
| MX2009001248A (es) | 2006-08-03 | 2009-02-11 | Nitec Pharma Ag | Tratamiento con glucocorticoide de liberacion prolongada de enfermedad reumatoide. |
| CN101970663A (zh) * | 2007-12-11 | 2011-02-09 | 科达治疗公司 | 受损伤口愈合的组合物和治疗 |
| WO2009085270A2 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions |
| CA2710375A1 (en) * | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Treatment of orthopedic conditions |
| JP2011524345A (ja) * | 2008-06-04 | 2011-09-01 | コーダ セラピューティクス， インコーポレイテッド | ギャップジャンクション調節化合物を用いる疼痛の治療 |
| RU2657535C2 (ru) | 2012-03-01 | 2018-06-14 | Ферстстринг Рисерч, Инк. | Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act) |
| EP3036005A4 (en) | 2013-08-21 | 2017-04-26 | The Board Of Regents Of The University Of Texas System | Compositions and methods for targeting connexin hemichannels |
| JP6683686B2 (ja) | 2014-08-22 | 2020-04-22 | オークランド ユニサービシーズ リミティド | チャネル調節剤 |
| WO2017147561A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Regents Of The University Of Texas System | CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF |
| CN111201247A (zh) | 2017-04-28 | 2020-05-26 | 奥克兰联合服务有限公司 | 治疗方法和新颖构建体 |
| CA3196342A1 (en) | 2020-10-22 | 2022-04-28 | Gautam Ghatnekar | Peptide formulations and ophthalmic uses thereof |
| WO2025030173A1 (en) * | 2023-08-03 | 2025-02-06 | Next Science IP Holdings Pty Ltd | Reducing inflammation in surgical site tissues |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1146908E (pt) * | 1999-01-27 | 2005-10-31 | David Dr Becker | Formulacoes que contem nucleotidos de anti-sentido para conexinas |
| JP2003238441A (ja) * | 2002-02-08 | 2003-08-27 | 英行 ▲高▼野 | 血管新生抑制剤 |
| AU2005210668A1 (en) * | 2004-01-30 | 2005-08-18 | Angiotech International Ag | Compositions and methods for treating contracture |
| CA2596412A1 (en) * | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
| US7767710B2 (en) * | 2005-05-25 | 2010-08-03 | Calosyn Pharma, Inc. | Method for treating osteoarthritis |
| KR20150072458A (ko) * | 2006-11-15 | 2015-06-29 | 코다 테라퓨틱스, 인크. | 상처 치유를 위한 개선 방법 및 조성물 |
| CN101970663A (zh) * | 2007-12-11 | 2011-02-09 | 科达治疗公司 | 受损伤口愈合的组合物和治疗 |
-
2008
- 2008-12-22 CA CA2710382A patent/CA2710382A1/en not_active Abandoned
- 2008-12-22 WO PCT/US2008/014022 patent/WO2009085271A2/en not_active Ceased
- 2008-12-22 JP JP2010539514A patent/JP2011507858A/ja active Pending
- 2008-12-22 AU AU2008343842A patent/AU2008343842A1/en not_active Abandoned
- 2008-12-22 US US12/809,980 patent/US20110243964A1/en not_active Abandoned
- 2008-12-22 EP EP08868893A patent/EP2242844A2/en not_active Withdrawn
-
2010
- 2010-07-21 ZA ZA2010/05218A patent/ZA201005218B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507858A5 (enExample) | ||
| JP2011507860A5 (enExample) | ||
| JP2011507861A5 (enExample) | ||
| JP2011507855A5 (enExample) | ||
| Thiede et al. | Pharmacokinetics of sustained-release and transdermal buprenorphine in Göttingen minipigs (Sus scrofa domestica) | |
| JP2009544585A5 (enExample) | ||
| JP4817495B2 (ja) | 外因性カンナビノイドでの痛みの制御 | |
| JP2005512976A5 (enExample) | ||
| RU2009122370A (ru) | Улучшенные способы и композиции для заживления ран | |
| CN109477109A (zh) | 靶向人lmna的寡核苷酸类似物 | |
| JP2006515351A5 (enExample) | ||
| HUE029677T2 (hu) | Készítmények centrálisan mediált émelygés és hányás kezelésére | |
| JP2011507856A5 (enExample) | ||
| JP2011507859A5 (enExample) | ||
| WO2008117268A2 (en) | A drug delivery device for providing local analgesia, local anesthesia or nerve blockade | |
| JP2010533705A5 (enExample) | ||
| JP2009519949A5 (enExample) | ||
| JP2024521091A (ja) | 褐色脂肪生成を誘導する方法及び組成物 | |
| CN107847565A (zh) | 用于肌肉减少症治疗的包括胰高血糖素样肽‑1 受体激动剂的药物组合物 | |
| WO2009150214A3 (en) | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease | |
| IL194500A0 (en) | Peptide substance enhancing capillaries resistance, pharmaceutical composition on its base and method of its application | |
| Chen et al. | Systemic penicillin as an experimental model of epilepsy | |
| JPH07508003A (ja) | 非経口投与用の安定化ソマトトロピン | |
| CN112156104B (zh) | 一种治疗抑郁症的药物 | |
| US20100105762A1 (en) | Therapeutic agent for periodontal disease and alveolar bone loss due to surgery |